GSK5764227 for Gastrointestinal Cancer

Recruiting at 3 trial locations

Overseen By EU GSK Clinical Trials Call Center

Age: 18+

Sex: Any

Trial Phase: Phase 1 & 2

Sponsor: GlaxoSmithKline

Must not be taking: Immunosuppressants, Antibody-drug conjugates

Disqualifiers: Malignancy, Cardiovascular disorders, Hypertension, Infection, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 17 months

200 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This study will check how well a new medicine, GSK5764227, works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.

Are You a Good Fit for This Trial?

This trial is for people with advanced gastrointestinal cancers that can't be removed by surgery. Participants must have had 1-2 prior treatments for colorectal cancer, show progression after the last treatment, and have at least one measurable tumor. They need to provide a fresh or archival tumor tissue sample, agree to use contraception, sign consent forms, and have good organ function with an ECOG performance status of 0 or 1.

Inclusion Criteria

I am willing to use birth control.

My organs are functioning well.

I have at least one measurable cancer lesion.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive GSK5764227, either high or low dose, to evaluate efficacy and safety

17 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

15 months

What Are the Treatments Tested in This Trial?

Interventions

• GSK5764227

Trial Overview The study tests GSK5764227's effectiveness and safety in individuals worldwide with advanced gastrointestinal cancer who've already tried other treatments. It aims to understand how patients respond to this new medication and how their bodies process it.

How Is the Trial Designed?

Group I: GSK5764227(high dose) Experimental Treatment 1 Intervention

Group II: GSK5764227 (low dose) Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

GlaxoSmithKline

Lead Sponsor

Trials

4,834

Recruited

8,389,000+

Headquarters

London, UK

Known For

Vaccines & Medicines

Top Products

**Advair (salmeterol, fluticasone propionate)**, **Shingrix (shingles vaccine)**, **Augmentin (amoxicillin/clavulanate potassium)**, **Ventolin (salbutamol sulfate)

Dame Emma Walmsley

GlaxoSmithKline

Chief Executive Officer since 2017

MA in Classics and Modern Languages from Oxford University

Dr. Hal Barron

GlaxoSmithKline

Chief Medical Officer since 2018

MD from Harvard Medical School